BroadOak Capital Partners is a boutique financial institution specializing in the life sciences sector, offering investment through BroadOak Asset Management and advisory services via BroadOak Partners. The company focuses on life sciences tools, diagnostics, and biopharma services, with a track record of over 100 investments and transactions since 2006.
- Pharmaceuticals
- Consumer Health
- Nutraceuticals
- Healthcare
- Biotechnology
- Diagnostics
- Medical Technology
- Artificial Intelligence
- Digital Health
- Oncology
Leadership
| Name | Title | ||
|---|---|---|---|
| Bill Snider | Partner |
in/billsniderbroadoak
|
|
| Partner |
|
|
|
| Managing Director |
|
|
|
| Managing Director |
|
|
Recent Transactions involving BroadOak Capital Partners
| Deal | Target | Platform | Buyer | Industry |
|---|---|---|---|---|
Spatial Biology CRO Flagship Biosciences Acquires Pharma Services Business from Interpace Biosciences |
Interpace Pharma Solutions |
Flagship Biosciences |
BroadOak Capital PartnersAmpersand Capital PartnersResearch Corporation Technologies |
Genomic Diagnostics |
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
The Lower and Middle Market M&A Platform
See how PrivSource can help you close more deals.
Learn more →